Impact of nivolumab on survival, tumour remission and long-term safety in patients with advanced melanoma

A dose-escalation, cohort expansion study with nivolumab in patients with advanced melanoma aimed to observe its impact on overall survival, long-term safety, and response duration after treatment discontinuation. The results are seen as remarkable for patients with treatment-resistant, advanced/metastatic melanoma, with overall survival comparing favourably to literature studies of similar patient populations. Responses were durable and persisted after drug discontinuation with acceptable long-term safety. Read more here.